SCHEMBL5912909

SCHEMBL5912909

CN1C(=O)CSc2ccc(C(N)=O)cc21

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.78
▸ SMN1; SMN2 Q16637 3/20 0.72
▸ POLB P06746 2/20 0.72
▸ MAPT P10636 11/20 0.60
▸ MEN1 O00255 6/20 0.60
▸ KMT2A Q03164 6/20 0.60
▸ ALDH1A1 P00352 3/20 0.55
▸ HTT P42858 4/20 0.54
▸ MAPK1 P28482 7/20 0.54
▸ ALOX15 P16050 2/20 0.54
▸ USP2 O75604 2/20 0.54
▸ TP53 P04637 2/20 0.54
▸ OPRM1 P35372 1/20 0.52
▸ OPRD1 P41143 1/20 0.52
▸ HSD17B10 Q99714 1/20 0.51
▸ CLK1 P49759 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ NPC1 O15118 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ RAB9A P51151 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2636675 0.88 LMNA (1.00) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL30270516 0.88 LMNA (1.00) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL24124207 0.87 LMNA (0.76) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL30270575 0.87 LMNA (0.76) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL5422370 0.84 POLB (1.00) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL10651410 0.83 LMNA (0.71) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL3999750 0.80 LMNA (0.61) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL7488353 0.78 POLB (0.70) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL433871 0.78 LMNA (0.63) LMNASMN1; SMN2POLBMAPTMEN1
SCHEMBL24124884 0.77 MAPT (0.64) LMNASMN1; SMN2POLBMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211636-A1 Macrolide Antibiotics ALIHODZIC SULEJMAN 2006-09-21 — — US disclosed
US-20050215495-A1 Macrolide antibiotics ALIHODZIC SULEJMAN 2005-09-29 — — US disclosed
US-20040077557-A1 Macrolide antibiotics GLAXO GROUP LIMITED (GB) 2004-04-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215495-A1 Macrolide antibiotics IL1R1, MRPL12, RPS21 LMNA 1672/4885SMN1; SMN2 3554/4885POLB 2625/4885
US-20060211636-A1 Macrolide Antibiotics IL1R1, MRPL12, RPS21 LMNA 1672/4885SMN1; SMN2 3554/4885POLB 2625/4885
US-20040077557-A1 Macrolide antibiotics MALT1, MRPL21, IL1R1 LMNA 1504/4885SMN1; SMN2 3041/4885POLB 2847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback